The Sickle Cell Clinical Trials Network: One Year In
The Hematologist Editor-in-Chief, Dr. Laura Michaelis, spoke with Drs. Charles Abrams and Sophie Lanzkron about a groundbreaking ASH initiative started approximate
Popping the Bubble: Promising Results From a Phase I-II Lentiviral Gene Therapy Trial for X-SCID
Drs. Arnold and Teachey review a phase I-II trial observing self-inactivating-lentiviral gene therapy in eight consecutive male infants newly diagnosed with X-linked severe
Drs. Ouseph and Kim discuss the utility of MRD measurements in the context of MM and the use of deep sequencing of clonotypic rearrangements by NGS to achieve greater analytical sensitivity in assessing MRD, and thus predicting outcomes in myeloma.
May-June 2019Volume 16, Issue 3
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology